- Home
- ALGS vs GANX Comparison
ALGS vs GANX Comparison
Compare ALGS & GANX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ALGS
- GANX
- Stock Information
- Founded
- ALGS 2018
- GANX 2017
- Country
- ALGS United States
- GANX United States
- Employees
- ALGS N/A
- GANX N/A
- Industry
- ALGS Biotechnology: Pharmaceutical Preparations
- GANX Biotechnology: Pharmaceutical Preparations
- Sector
- ALGS Health Care
- GANX Health Care
- Exchange
- ALGS Nasdaq
- GANX Nasdaq
- Market Cap
- ALGS 53.0M
- GANX 53.4M
- IPO Year
- ALGS 2020
- GANX 2021
- Fundamental
- Price
- ALGS $7.70
- GANX $1.73
- Analyst Decision
- ALGS Strong Buy
- GANX Strong Buy
- Analyst Count
- ALGS 1
- GANX 5
- Target Price
- ALGS $70.00
- GANX $8.00
- AVG Volume (30 Days)
- ALGS 62.6K
- GANX 307.8K
- Earning Date
- ALGS 08-06-2025
- GANX 08-12-2025
- Dividend Yield
- ALGS N/A
- GANX N/A
- EPS Growth
- ALGS N/A
- GANX N/A
- EPS
- ALGS N/A
- GANX N/A
- Revenue
- ALGS $3,174,000.00
- GANX N/A
- Revenue This Year
- ALGS N/A
- GANX N/A
- Revenue Next Year
- ALGS $51.55
- GANX N/A
- P/E Ratio
- ALGS N/A
- GANX N/A
- Revenue Growth
- ALGS N/A
- GANX N/A
- 52 Week Low
- ALGS $3.76
- GANX $0.95
- 52 Week High
- ALGS $46.80
- GANX $3.19
- Technical
- Relative Strength Index (RSI)
- ALGS 46.70
- GANX 57.81
- Support Level
- ALGS $7.31
- GANX $1.45
- Resistance Level
- ALGS $7.85
- GANX $1.64
- Average True Range (ATR)
- ALGS 0.75
- GANX 0.15
- MACD
- ALGS -0.09
- GANX 0.02
- Stochastic Oscillator
- ALGS 35.03
- GANX 45.08
About ALGS Aligos Therapeutics Inc.
Aligos Therapeutics Inc is a clinical stage biopharmaceutical company. It is engaged in developing novel therapeutics to address unmet medical needs in viral and liver diseases, including chronic hepatitis B and coronaviruses, and therapeutics for nonalcoholic steatohepatitis (NASH). The company's pipeline includes ALG-010133, ALG-000184, ALG-020572 and ALG-055009, among others.
About GANX Gain Therapeutics Inc.
Gain Therapeutics Inc is a biotechnology company developing novel small molecule therapeutics to treat diseases across several therapeutic areas, including, lysosomal storage disorders, central nervous system disorders, metabolic disorders, and oncology. The company's clinical-stage product candidate, GT-02287, is being developed for the treatment of GBA1 Parkinson's disease. The company uses its computational target and drug discovery platform, Magellan, to discover novel allosteric binding sites on proteins implicated in disease and to identify proprietary small molecules that bind these sites to modulate protein function and treat the underlying cause of the disease. Geographically, the company operates in Switzerland, Spain, the United States, and Australia.